Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Burkitt Lymphoma 1

Interventions

Carboplatin 14pembrolizumab 12Gemcitabine 11Cisplatin 11Rituximab 8durvalumab 7Pemetrexed 6Nivolumab 6osimertinib 5atezolizumab 5Specimen Handling 5Paclitaxel 5Dexamethasone 5amivantamab 4Prednisone 4Ipilimumab 4Cyclophosphamide 4Bortezomib 4Bendamustine Hydrochloride 4tremelimumab 3trastuzumab deruxtecan 3olaparib 3niraparib 3lazertinib 3entrectinib 3enfortumab vedotin 3daratumumab 3belzutifan 3alectinib 3acalabrutinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × N,N-dicyclohexyl-isoborneol-10-sulfonamide × 90 days × Clear all
NCT02003222 2026-05-28

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
488 enrolled 13 charts 1 FDA
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡